Smithkline Beecham Corporation

Glaxosmithkline LLC

Darryl Lynn McDougald

Amarjit Sab Randhawa

Curt Dale Haffner

Rodolfo Cadilla

Philip Stewart Turnbull

Andrew Lamont Larkin

Eugene Lee Stewart

John Albert Ray

Huiquiang Zhou

Katherine Stetson

James Martin Lenhard

Steven Michael Reister

Istvan Kaldor

David Norman Deaton

Aaron Bayne Miller

This invention relates to non-steroidal compounds that are modulators of androgen receptor, and also to the methods for the making and use of such compounds.

Chemical compounds

The present invention relates to novel compounds, their use for inhibiting serine proteases, such as dipeptidyl peptidases, such as dipeptidyl peptidase IV (DPP-IV) and to methods for their production and their therapeutic utility 

Pyrrolidines as dipeptidyl peptidase inhibitors

The present invention relates to novel compounds, their use for inhibiting post prolin/analine-cleaving proteases, such as serine proteases, such as dipeptidyl peptidases, such as dipeptidyl peptidase IV (DPP-IV), and to methods for their production and their therapeutic utility.

Fluoropyrrolidines as dipeptidyl peptidase inhibitors

The present invention includes novel retinoid compounds that have selectivity as RXR agonists on one or more isoforms of RXR, currently, RXR&#x3b1;, RXR&#x3b2;, or RXR&#x3b3;. The present compounds, and pharmaceutical compositions incorporating these compounds, therefore, are effective in treating conditions mediated by RXRs. Among other physiological responses, the compounds of the present invention reduce blood glucose and maintain body weight, and, thus, are useful for the treatment of diabetes (NIDDIM) and obesity.

Selective RXR ligands

The present invention relates to novel compounds, their use for inhibiting serine proteases, such as dipeptidyl peptidases, such as dipeptidyl peptidase IV (DPP-IV) and to methods for their production and their therapeutic utility.

Growing community of inventors

Durham, NC, United States of America

Darryl Lynn McDougald